GLMD Galmed Pharmaceuticals Ltd. gains 86% Jun 25, 2018

Posted By: Rajesh Srivastava - Monday, June 25, 2018

Share

& Comment

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of a once-daily, oral therapy for the treatment of liver diseases. It is developing Aramchol, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.http://www.priceseries.com/trade/GLMD-Galmed-Pharmaceuticals-Ltd-stock-gains-86-percent-a-Trade-Record-by-priceSeries-2018061120180625.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.